Diagnostic tests for toxoplasmosis in women having history of fetal wastage

One hundred pregnant patients having history of fetal wastage and 20 pregnant women with no history of fetal wastage as control, were serologically examined for the total toxoplasma specific antibody titer using the direct agglutination test. Those who had significant high antibody titer were re-examined for anti-toxoplasma IgM antibodies using the IgM microassay. It was found that among the selected cases 42% were seropositive for the total toxoplasma specific antibody titer, while 25% were seropositive among the control group. This was statistically insignificant. On the other h and, 25% of the selected cases were seropositive for the anti-toxoplasma IgM antibody titer, while 10% of the control group were seropositive. This was also statistically insignificant

Evaluation of ultrasonography and laparoscopy in the diagnosis of pelvic masses

Fifty patients with small pelvic masses were subjected to ultrasonographic examination using the full bladder technique. Confirmation of the results of the scan was then made by laparoscopy. According to the results of ultrasonography, the study cases were classified into cystic, mixed and solid pelvic masses. The cystic masses constituted 26 of the study cases. The ultrasonic accuracy for cystic masses was 92.3% [24 out of 26 cases]. The mixed masses constituted 20 cases. The accuracy of ultrasonography for mixed masses was 50% [10 out of 20 cases]. The solid masses constituted 4 cases. The accuracy of ultrasonography for solid masses was 100% [4 out of 4 cases]. The overall diagnostic accuracy of ultrasonography as confirmed by laparoscopy was found to be 76% [38 out of 50 cases]

comparative clinical trial of two once-a month injectable contraceptives [cyclofem and mesigyna]

A comparative clinical trial of two once-a-month injectable contraceptives [cyclofem and mesigyna] was carried out in Shatby University Hospital. A total of 297 women [150 for cyclofem and 147 for mesigyna] were recruited in the study and were followed for a period of 12 months. The two groups of women were comparable in all aspects, 86.9% of women continued until the end of 12 months. The contraceptive efficacy for both regimen was 100%. More than 90% of women in both groups did not have any complaints during the 12 follow-up visits. No significant differences was found between the two groups as regards continuation and discontinuation rates, menstrual pattern, blood pressure [systolic and diastolic] and body weight changes. The results showed that cyclofem and mesigyna are highly effective contraceptives that caused side effects in less than 10% of users and were acceptable to women as evidenced by a high continuation rate over the study period